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84Randomized Trial of Hydroxychloroquine for Newly
Diagnosed Chronic Graft-versus-Host Disease in
Children: A Children’s Oncology Group Study
Andrew L. Gilman,1 Kirk R. Schultz,2 Frederick D. Goldman,3 George E. Sale,4
Mark D. Krailo,5,6 Zhengjia Chen,7 Bryan Langholz,5,6 David A. Jacobsohn,8 Ka-Wah Chan,9
Robin E. Ryan,10 Michael Kellick,11 Steven M. Neudorf,12 Kamar Godder,13
Eric S. Sandler,14 Indira Sahdev,15 Stephan A. Grupp,16 Jean E. Sanders,4 Donna A. Wall17The Children’s Oncology Group conducted a multicenter Phase III trial for chronic graft-versus-host disease
(cGVHD). The double-blind, placebo-controlled, randomized study evaluated hydroxychloroquine added to
standard therapy for children with newly diagnosed cGVHD. The study also used a novel grading and re-
sponse scoring system and evaluated clinical laboratory correlates of cGVHD. The primary endpoint was
complete response (CR) after 9 months of therapy. Fifty-four patients (27 on each arm) were enrolled before
closure because of slow accrual. The CR rate was 28% in the hydroxychloroquine arm versus 33% in the pla-
cebo arm (odds ratio [OR]5 0.77, 95% confidence interval [CI]: 0.20-2.93, P5.75) for 42 evaluable patients.
For 41 patients with severity assessment at enrollment, 20 (49%) were severe and 18 (44%) moderate ac-
cording to the National Institutes of Health Consensus Conference global scoring system. The CR rate
was 15% for severe cGVHD and 44% for moderate cGVHD (OR 5 0.24, 95% CI: 0.05-1.06, P 5 .07).
Although the study could not resolve the primary question, it provided important information for future
cGVHD study design in this population.
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Chronic GVHD (cGVHD) is the major cause of
morbidity and nonrelapse mortality (NRM) after he-
matopoietic stem cell transplantation (HSCT) [1].His-
torically, complete response rates of cGVHD after 9
months of primary therapy are 33% to 37% [2],
suggesting that better therapies are needed. Progress
in treating cGVHD has been limited by the clinical
complexity of the disease, lack of knowledge about
the underlying pathophysiology, and paucity of Phase
III clinical trials. A 2005 National Institutes of Health
(NIH) Consensus Development Project on criteria
for clinical trials of cGVHD provided guidelines
for many of the diagnostic, response criteria, and
supportive care issues [3-7]. Most Phase III studies
of therapy for cGVHD have been conducted at
single institutions. Landmark studies include rando-
mized trials of prednisone versus prednisone and aza-
thioprine [2], and prednisone versus prednisone and
cyclosporine [8]. Two trials of thalidomide and 1 trial
of mycophenolate mofetil (MMF) were closed before
reaching their target accrual [9-11]. Despite these
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over the last 20 years [12].
Hydroxychloroquine (HCQ) is a 4-aminoquinoline
antimalarial drug that has activity as salvage therapy for
steroid-resistant/dependent cGVHD [13]. A multi-
institutionalPhase II trial ofHCQinchildren and adults
with steroid-resistant or steroid-dependent cGVHD
utilizing HCQ dosing of 800 mg/day or 12 mg/kg/day
(if weight \50 kg) demonstrated a response rate of
53% (3 complete response [CR] and 14 partial re-
sponses) in 32 evaluable patients. Responses were most
notable in skin, oral, and liver cGVHD, and there was
no significant toxicity associated with the HCQ.
HCQ interferes with antigen processing and pre-
sentation [14], decreases production of interleukin
(IL)-1, IL-6, and tumor necrosis factor (TNF)-
a [15,16], and decreases proliferation and cytotoxicity
resulting from allorecognition [17]. HCQ also inhibits
calcium signaling in T cells [18]. HCQ, and the closely
related drug chloroquine is synergistic with cyclo-
sporine and tacrolimus in vitro for suppressing
alloreactive responses [17-21].
Based on the mechanisms of action of HCQ and
the results of the Phase II study for cGVHD, we
designed a randomized, double-blinded, placebo-
controlled study of HCQ added to standard therapy
for children with newly diagnosed extensive cGVHD.
The study was designed as a multicenter study because
of the low incidence of cGVHD in children [22] and to
explore the feasibility of conducting multicenter stud-
ies of cGVHD. The study also used a novel scoring
system for grading cGVHDmanifestations and overall
severity that is similar to that later proposed by the
NIH Consensus Development Project [6]. Finally,
there was a large research laboratory component to
the study with the goal of advancing the understanding
of cGVHD pathophysiology.METHODS
Patient Enrollment
The study was conducted by the Children’s Oncol-
ogy Group from April 2002 to April 2005. Subjects
were less than 30 years of age at time of study entry,
had newly diagnosed extensive cGVHD, and had re-
ceived a bone marrow, peripheral blood stem cell
(PBSC), or cord blood (CB) transplantation from a
family member or unrelated donor. Confirmation of
cGVHD by biopsy was required. Patients could be
taking steroids at a dose #2 mg/kg/day of prednisone
or an equivalent dose of another steroid for the treat-
ment or prophylaxis of acute GVHD (aGVHD),
cyclosporine or tacrolimus, and other immunosup-
pressants for the treatment of aGVHD. Patients
were required to have an absolute neutrophil count
(ANC)$1000/mm3 (unless because of cGVHD), ade-quate renal function, Lansky or Karnofsky perfor-
mance score of $50, and a life expectancy of at least
2 months. Patients were not eligible if they had prior
systemic treatment for extensive cGVHD, an uncon-
trolled infection, relapse of malignancy after transplan-
tation, lysosomal storage disorder, glucose 6-phosphate
dehydrogenase (G6PD) deficiency, psoriasis, or if they
were pregnant. Informed consent was obtained from
the patient or guardian in accordance with institutional
policies and as approved by the U.S. Department of
Health and Human Services. The trial was registered
at ClinicalTrials.gov with identifier NCT00031824
on May 8, 2002.Study Design
The study was a randomized, double-blinded, pla-
cebo-controlled trial. Sequential block randomized
(block size of 2) assignment was performed electroni-
cally at the statistical coordinating center with the
result of the randomization transmitted to the study
pharmacist who then dispensed the study drug (HCQ
or placebo in the same tablet form) in a blinded fashion
to the treating physician. All patients received a stan-
dardized treatment of steroids and cyclosporine or
tacrolimus, and were randomized to receive HCQ or
matching placebo. Any systemic immunosuppressive
therapy other than steroids, cyclosporine, or tacroli-
mus was discontinued at study entry. The use of
topical steroids was permitted. Patients received
prednisone 1 mg/kg/day for 2 weeks and then the
dose was tapered to 1 mg/kg every other day over the
next 6 weeks. Originally, the prednisone dose re-
mained at 1 mg/kg every other day until 9 months after
starting therapy. Patients receiving prednisone $0.5
mg/kg/day at study entry had a slower steroid taper
and received methylprednisolone 15 mg/kg i.v. weekly
4. Patients receiving prednisone 0.5-1 mg/kg/day,
received 4 weeks of prednisone 1 mg/kg/day before
the taper. Patients receiving prednisone .1-2 mg/
kg/day remained on the same dose for 4 weeks fol-
lowed by a taper of 10% weekly until a dose of 1 mg/
kg/day was reached. The prednisone dose was then
weaned to 1 mg/kg every other day over the next 6
weeks. Patients who had worsening of cGVHD during
the steroid taper had the dose increased to the dose
given 2 weeks earlier. This dose was continued for 2
weeks and then the taper was resumed. If the cGVHD
progressed, the patient was taken off protocol therapy.
An amendment in May 2003 incorporated a second
steroid taper starting at 6 months after study entry
that decreased the prednisone dose to 0.5 mg/kg every
other day over 2.5 months.
Cyclosporine and tacrolimus were given at stan-
dard doses with target trough levels of 200-300 ng/
mL and 5-15 ng/mL, respectively. The HCQ/placebo
dose was 12 mg/kg/day (max 1000 mg), divided into
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stasis (25% and 50% reductions for bilirubin .6 and
.12 the upper limit of normal, respectively). The
dose was also adjusted for decreased renal function
(25% and 50% reductions for creatinine $1.5 and
$2 the upper limit of normal, respectively). The
HCQ dosing was the same as that used for the Phase
II study [13]. HCQ and the matching placebo were
purchased from Sanofi Pharmaceuticals (New York,
NY). HCQ was provided under terms of a Food and
Drug Administration Investigational New Drug
(IND) application #44,717 issued to 1 of the authors
(A.L.G.).
Central Pathology Review
Biopsy specimens were reviewed by George Sale,
MD, a GVHD pathology expert, at Fred Hutchinson
Cancer Research Center, Seattle, WA. Biopsies were
reviewed centrally for retrospective analysis only.
Clinical GVHD Review
A panel of 5 members of the study committee
(A.L.G., D.A.W., K.R.S., F.D.G., D.A.J.) reviewed
the clinical findings at diagnosis. This included photo-
graphs of skin and oral involvement when available.
Required Observations
At study entry, patients had complete blood counts,
chemistries, liver function tests, quantitative immu-
noglobulins, direct and indirect Coombs, antinuclear
antibody (ANA), anti-double-stranded DNA (anti-
dsDNA), baseline ophthalmological exam, complete
evaluation for cGVHD, and a health-related quality
of life (QOL) assessment. Complete evaluations for
cGVHD and response were performed after 2, 6, and
9 months of therapy. ANA, anti-dsDNA, and Coombs
tests were only repeated if abnormal at entry. Ophthal-
mological exams with attention to possible HCQ-
related retinal toxicity were done at 6 and 12 months.
Response Criteria
Responses were evaluated after 2, 6, and 9 months
of therapy and categorized as complete response (com-
plete clinical resolution of all reversible GVHD man-
ifestations), partial response (complete clinical
resolution in at least 1 involved site but persistent dis-
ease [not progression] in other sites), stable disease (no
clinical improvement in GVHD manifestations and
lack of clinical worsening), progressive disease (clinical
worsening of GVHD manifestations). Patients were
considered not evaluable for response at 9 months if
they terminated protocol therapy before this time for
reasons not related to progression of cGVHD, toxic-
ity, or relapse.
Improvement and worsening were assessed using
a grading system for each involved organ (Table S1,online only). The grades included 0 (not involved), 1
(mild), 2 (moderate), and 3 (severe), and definitions
for the severity grading were provided for each organ.
Clinical response data were reviewed and adjudicated
centrally.
Off Protocol Therapy Criteria
Patients were removed from protocol therapy for
(1) progressive cGVHD after 2 months of therapy,
(2) life-threatening progression of cGVHD after $2
weeks, (3) inability to complete steroid taper because
of recurrent cGVHD flare, (4) no response (stable dis-
ease) after 6 months of protocol therapy (amended to 2
months in June 2004; only 2 patients affected by this
change), (5) lack of a complete response after 9 months
of therapy, (6) completion of treatment (9 months of
protocol therapy and completion of study drug taper-
ing without a flare, and completion of 9 months of
follow-up) for complete responders, (7) Grade III or
IV toxicity not resolving with dose modification or dis-
continuation of a protocol drug, or any visual impair-
ment attributable to HCQ, (8) intercurrent illness that
prevented further administration of treatment, (9) re-
lapse of malignancy, (10) withdrawal of consent, (11)
lost to follow-up, or (12) death.
Study Endpoints
The primary study endpoint was the complete re-
sponse rate after 9 months of therapy. Secondary end-
points included event-free survival (EFS), overall
survival (OS), and grade 3 and 4 toxicity.
Statistical Considerations
The primary question of treatment effect was as-
sessed by comparing the proportion of CR patients
in the HCQ arm to the proportion of CR patients in
the placebo arm. The target accrual was 232 patients
to have an 80% power at a5 0.05 (one-sided) to detect
an odds ratio (OR) of 2.0 comparing CR rates in the
HCQ arm to the placebo arm. The response OR was
estimated as the cross-product from the 2  2 table
of response (CR vs not CR) by treatment group with
95% Wald confidence intervals (95% CI) estimated
in the usual way. The Fisher exact test was used for
the response rate comparisons [23]. A post hoc analysis
was performed for CR 1 partial response (PR) for the
2 treatment arms in a similar fashion. Standard chi-
square tests were employed to identify significant
prognostic factors for response [24]. The probability
of survival as a function of time since enrollment was
calculated using the method of Kaplan and Meier
[25]. The survivor function was compared across treat-
ment regimens using the log-rank test [26]. A post hoc
analysis was performed to evaluate the relationship of
response rate and degree of severity based on the
global scoring system of cGVHD severity proposed
Table 1. Patient Characteristics
By Treatment Arm
Placebo
(N 5 27)
HCQ
(N 5 27) P Value
Age (median, range) 11 (1,21) 13 (3,20) .21
Sex 1.00
Male 19 (70) 18 (67)
Female 8 (30) 9 (33)
Diagnosis .41
ALL 16 (59) 12 (44)
AML/MDS 8 (30) 7 (26)
Chronic myelogenous leukemia 0 (0) 4 (15)
Other malignant disease 1 (4) 1 (4)
Nonmalignant disease 2 (7) 3 (11)
Donor type 1.00
Related 12 (44) 11 (41)
Unrelated 15 (56) 16 (59)
Stem cell source .08
Bone marrow 9 (33) 15 (56)
PBSC 14 (52) 6 (22)
Cord blood 4 (15) 6 (22)
Prior acute GVHD .88
Acute GVHD Grade (I-II) 12 (44) 11 (41)
Acute GVHD Grade (III-IV) 6 (22) 5 (19)
Immunosuppression at study entry
Steroids 11 (41) 10 (37) 1.00
Cyclosporine 11 (41) 6 (22) .24
Tacrolimus 5 (19) 8 (30) .53
Months from transplant to cGVHD
(median, range)
6 (3,24) 6 (3,14) 1.00
Onset of cGVHD .76
Progressive 4 (15) 5 (19)
Quiescent 13 (48) 10 (37)
De novo 10 (37) 12 (44)
Platelets <100,000/mL 7 (26) 6 (22) 1.00
Site of cGVHD at study entry
Lichenoid skin score .24
1 5 (19) 3 (12)
2 3 (12) 1 (4)
3 3 (12) 2 (8)
Sclerodermatous skin score .73
1 2 (8) 2 (8)
2 2 (8) 2 (8)
3 0 (0) 2 (8)
Oral score .78
1 12 (46) 5 (19)
2 4 (15) 8 (31)
3 1 (4) 2 (8)
Ocular score .78
1 4 (15) 6 (23)
2 10 (38) 5 (19)
3 0 (0) 1 (4)
Bilirubin score .74
1 3 (11) 4 (15)
2 2 (8) 2 (8)
3 0 (0) 1 (4)
Alkaline phosphatase score 1.00
1 3 (12) 4 (15)
2 3 (12) 2 (8)
3 0 (0) 0 (0)
ALT score .09
1 8 (31) 4 (15)
2 6 (23) 2 (8)
3 0 (0) 1 (4)
Gastrointestinal symptoms 8 (31) 15 (58) .09
Diarrhea score .10
1 4 (15) 7 (27)
2 0 (0) 3 (11)
3 0 (0) 0 (0)
Weight loss score .14
1 5 (19) 9 (35)
2 1 (4) 2 (8)
3 0 (0) 1 (4)
Pulmonary involvement 5 (19) 7 (27) .74
(Continued )
Table 1. (Continued )
By Treatment Arm
Placebo
(N 5 27)
HCQ
(N 5 27) P Value
Contractures score 1.00
1 0 (0) 0 (0)
2 5 (19) 3 (12)
3 0 (0) 2 (7)
Performance score <90 15 (58) 12 (46) .58
Overall cGVHD score (median,
range)
12 (3, 23) 11 (4, 22) .77
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leuke-
mia; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cell;
GVHD, graft-versus-host disease; cGVHD, chronic graft-versus-host
disease; ALT, alanine aminotransferase; HCQ, hydroxychloroquine.
Number in parentheses is percentage; overall cGVHD score calculated
by adding individual scores from Table S1. Data was not available for 1
patient for history of malignancy, and data was not available for overall
score for 2 patients.
P values for differences in characteristics scored 0-3 are from Fisher ex-
act test of score 1-3 versus score 0. Percentages are from patients with
nonmissing data.
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curred after the initiation of this study [3]. The statis-
tical packages SAS (SAS Institute, Cary, NC) and
STATA (Stata Corporation, College Station, TX)
were used for all data management and statistical anal-
ysis.RESULTS
When the study was closed because of slow ac-
crual, 54 patients had been enrolled with 27 assigned
to each treatment arm. The participant flow diagram
is shown in Figure S1 (online only). None of the pa-
tients were lost to follow-up. Patients who were (1)
withdrawn from the study at the request of the patient
or parent/guardian (n 5 5) or (2) did not complete
therapy because of study closure (n 5 7) were consid-
ered not evaluable for the primary response endpoint.
Patient Characteristics
Among 54 enrolled patients, 37 (69%) were male
and 17 (31%)were female. Themedian age was 12 years
(range: 1-21). The stem cell source was bone marrow
(BM) (n5 24), PBSCs (n5 20), or CB (n5 10).Donors
were related in 43% of cases and unrelated in 57%.
Forty-nine patients had received a transplant for malig-
nant disease and 5 patients for nonmalignant disease.
Thirty-four patients (63%) had a history of aGVHD,
and 9 patients (17%) had progressive onset of cGVHD.
The median time from transplantation to diagnosis of
cGVHD was 6 months (range: 3-24). Twenty-one pa-
tients (39%) were receiving steroids at study entry.
Thirty patients (56%) were receiving cyclosporine or
tacrolimus, and 3 (6%)were receivingMMFat study en-
try. Details by study arm are provided inTable 1. There
Table 2. Grade 3 and 4 Toxicities Occurring in >10% in Either
Arm
88 Biol Blood Marrow Transplant 18:84-91, 2012A. L. Gilman et al.were no significant differences for any of these parame-
ters between the 2 arms.Toxicity Type
Treatment
Placebo HCQ
Number Percent Number Percent
Hypertension 4 14.8 4 14.8
Elevated GGT 3 11.1 2 7.4
Elevated ALT 7 25.9 2 7.4
Anemia 3 11.1 1 3.7
Thrombocytopenia 4 14.8 0 0
Infection without neutropenia 5 18.5 5 18.5
HCQ indicates Hydroxychloroquine; GGT, gamma glutamyl transferase;
ALT, alanine aminotransferase.Clinical Manifestations of cGVHD
Data regarding clinical manifestations at study en-
try were available for 52 patients. The proportion of
patients with each manifestation is shown in Table 1.
Several factors have been correlated with a worse prog-
nosis for patients with cGVHD [27]. The proportion
of patients with these adverse prognostic factors at
study entry was: lichenoid rash involving .50% of
the body surface area (9%), bilirubin .1.2 mg/dL
(23%), progressive onset of cGVHD (17%), platelet
count\100 K/mL (24%), presence of diarrhea/gas-
trointestinal (GI) involvement (27%/44%), andweight
loss (35%).
Eosinophil counts, IgG levels, and ANA titers
were available formost patients at the time of diagnosis
of cGVHD. Eosinophilia (absolute eosinophil count
.500/mL) was present in 40% (18 of 45) of patients.
Hypergammaglobulinemia (IgG level greater than
the upper limit of normal) was present in 23% (11 of
48) of patients. None of these patients was receiving
intravenous gammaglobulin. An ANA titer of $1:80
was present in 28% (12/43) of patients, and 9 of these
patients had titers $1:160. At presentation, 62%
(30/48) of patients had at least 1 of these 3 findings.Response Data
Among 54 enrolled patients, 42 (18 in HCQ arm
and 24 in placebo arm) were evaluable for response.
Twelve patients were not evaluable for response: 7 pa-
tients had not been in the study for 9 months when the
study was closed, and 5 patients were withdrawn at pa-
rental request. Out of the 42 evaluable patients, 13
(31%) had a CR at 9 months and 18 (43%) had a CR
or a PR. The rate of CR at 9 months was 28% (5 of
18) in the HCQ arm and 33% (8 of 24) in the placebo
arm (OR 5 0.77, 95% CI: 0.20-2.93, P 5 .75). The
rate of CR 1 PR at 9 months was 39% (7/18) in the
HCQ arm and 46% (11/24) in the placebo arm
(OR 5 0.75, 95% CI: 0.22-2.60, P 5 .76).Toxicity Data
All patients were evaluable for toxicity. Grade 3/4
toxicities, which occurred in more than 10% of pa-
tients, included hypertension (15%), elevated ALT
(17%), and infection without neutropenia (18.5%).
Grade 3/4 avascular necrosis and hyperglycemia each
occurred in 4% of patients. There were no statistically
significant differences between the 2 arms for grade 3/
4 toxicities. Toxicities occurring in more than 10% of
patients on either arm are shown in Table 2. There
were no serious toxicities that were attributed to
HCQ. Importantly, although retinal toxicity hasbeen reported with HCQ, it was not seen in the 27
patients treated with HCQ.
Infections
There were 13 grade 3/4 infections in 12 (22%)
patients (6 in each treatment arm). Three deaths that
occurred during protocol therapy were associated
with infection. Two of these were because of fungal in-
fection and the organism was not known for the third.
Central Pathological and Clinical Review
Biopsy specimens were reviewed centrally. Speci-
mens were reviewed for 37 of 54 (68%) patients en-
rolled on the study. Biopsies were from skin (n 5
25), oral/lip (n 5 9), liver (n 5 7), GI tract (n 5 5),
lung (n 5 1), and lacrimal gland (n 5 1). Biopsies
from more than 1 site were submitted for some pa-
tients. There was a high level of concordance between
the central and institutional diagnosis of GVHD: 36 of
37 (97%) patients and 47 of 48 (98%) biopsies.
Clinical manifestations present at diagnosis and
photographs when available were reviewed by a clinical
review panel to evaluate the clinical diagnosis of
cGVHD. Data were available for 46 of 54 (85%) pa-
tients at the time of the review. Photographs of skin
and/or oral findings were available for 19 patients. A
clinical diagnosis of cGVHD was confirmed for 45
of 46 (98%) patients for whom data were available.
Survival Data
Four of 54 (7%) patients died while on protocol
therapy or within 1 month of discontinuation of ther-
apy. The cause of death included progressive GVHD
(n 5 1), GVHD and infection (n 5 1), and infection
(n 5 2). The cause of death for 8 patients who died
at a later time was relapse of malignancy or complica-
tion of treatment of relapse (n 5 5), GVHD (n 5 1),
GVHD and infection (n 5 1), pulmonary fibrosis
(n 5 1), and lung disease not otherwise specified
(n 5 1). As seen in Figure 1, there is no evidence of
Figure 1. Overall survival of patients by treatment group.
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patients (P 5 .41).
Correlation of Response and cGVHD Severity
Patients were retrospectively scored as having
mild, moderate, or severe cGVHD based on the global
scoring system recommended by the NIH Consensus
Development Project on cGVHD [3]. There are
small differences in some of the organ-specific grades
between our grading table (Table S1, online only)
and the one proposed by the Consensus. However,
this did not affect the overall grading category for
any patient.
For the 41 evaluable patients for whom grading
data were available, 20 (49%) were graded as severe,
18 (44%) as moderate, and 3 (7%) as mild. The CR
rate was 44% for patients with moderate cGVHD
and 15% for patients with severe cGVHD (OR 5
0.24, 95% CI: 0.05-1.06, P 5 .07). The CR 1 PR re-
sponse rate was 56% for patients with moderate
cGVHD and 30% for patients with severe cGVHD
(OR 5 0.39, 95% CI: 0.11-1.41, P 5 .18).DISCUSSION
We report the first Phase III trial of cGVHD con-
ducted solely in children. The study was designed to
evaluate a therapeutic question, but also was the first
study to explore the feasibility of conducting a multi-
center Phase III trial for cGVHD. The study incorpo-
rated a grading system and central pathology and
clinical review to address this issue. The study per-
formed extensive immunological testing to evaluate
the pathophysiology of cGVHD and these results
have been published [28-30]. Despite not achieving
the primary endpoint, the study provided data,
including response rates with standard therapy and
the correlation of local and central pathology, thatwill be useful for the design of future studies of
cGVHD.
The primary aim of the study was to determine if
the addition of HCQ to standard therapy, including
prednisone and a calcineurin inhibitor, could improve
the complete response rate of cGVHD after 9 months
of therapy. This endpoint, which had been used for
most Phase III studies before the initiation of our
study, was chosen to allow sufficient time for maximal
clinical response and for steroid tapering. The primary
aim was not able to be addressed with adequate statis-
tical power because of the limited patient accrual, but
there was no suggestion of any significant difference
between the 2 treatment arms. Several factors may
have contributed to the suboptimal accrual. The eligi-
bility criteria were complex and strict. In addition, the
participating investigators struggled with differentiat-
ing the frequently insidious onset of cGVHD from
persistence or exacerbation of aGVHD. This resulted
in steroid pretreatment that made potential study sub-
jects ineligible for the trial. In an attempt to isolate the
specific impact of HCQ and to ensure that the arms
were similar, the treatment plan rigidly controlled ste-
roid dosing and tapering. The participating centers
found this study requirement challenging because of
competing reasons for which steroid dosing is adjusted
(eg, toxicity, risk of relapse). Of note, subsequent mul-
ticenter trials for cGVHD have also struggled with ac-
crual.
The study provided the only data available for re-
sponse rates of children with newly diagnosed exten-
sive cGVHD treated with standard therapy in
a multicenter trial. The central clinical and pathology
review to confirm the diagnosis of cGVHD showed ex-
cellent correlation between the local institution and
central review. The results support multicenter studies
of cGVHD and the use of institutional pathology for
these trials.
The study used a unique scoring system for grad-
ing cGVHD manifestations similar to the one later
proposed by the NIH Consensus Development Pro-
ject [3]. There are small differences in some of the
organ-specific grades between the scoring systems,
but this did not affect the overall grading category
for any patient. We were able to use the information
gathered in our scoring system to analyze the patients
according to the NIH Consensus global scoring sys-
tem (mild, moderate, and severe) of cGVHD severity
[3]. Our data suggest that the NIH Consensus global
scoring system for cGVHD severity for patients with
severe or moderate cGVHD correlates with the likeli-
hood of response after 9 months of therapy. There
were too few patients with mild disease to evaluate
this group. Another study retrospectively evaluated
the correlation between disease severity according to
this scoring system and the ability to discontinue im-
munosuppression, which is an alternative endpoint to
Table 3. Phase III Studies of Chronic Graft-versus-Host Disease Therapy
Number of Patients
HLA-Identical Sibling
Donor
Progressive Onset of
cGVHD
Platelet Count
<100,000/mL CR at 9 Months CR + PR at 9 Months
This report 54 61% 17% 28% 33% 44%
Sullivan [2] 126 94% 18% None 35% 63%
Koc [8] 287 68% 16% None N/A N/A
Arora [10] 54 63% 17% 37% 52% at 1 year 79% at 1 year
Martin [11] 151 51% 10% 22% N/A N/A
HLA indicates human leukocyte antigen; cGVHD indicates chronic graft-versus-host disease; CR, complete response; CR + PR, complete or partial re-
sponse; N/A, not available.
Number in brackets is the reference number.
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were significantly less likely to be able to discontinue
immunosuppression [31]. Additional studies correlat-
ing response rates and cGVHD severity are warranted.
The ability to identify patients unlikely to respond to
standard therapy is important because it would support
these patients being considered as candidates for stud-
ies of novel therapies at the time of diagnosis.
There is a paucity of Phase III studies of therapy
for newly diagnosed cGVHD. A summary of these
studies is shown in Table 3. Comparison between
these studies is difficult because of differences in the
proportion of patients with extensive cGVHD, sites
of cGVHD involvement, severity, and type of onset
of cGVHD, donor types, and other prognostic factors.
There are also differences in response criteria and
study endpoints, andmost of the studies are single cen-
ter studies. For example, a study reported by Sullivan
et al. [2] in 1988 evaluated the addition of azathioprine
to prednisone. Thirty-nine percent of the patients had
subclinical cGVHD (GVHD on blind biopsy without
clinical evidence of cGVHD) when therapy was
started. The response definition was stricter than other
studies, with a CR defined as clinically inactive
cGVHD and a negative biopsy and a PR defined as
clinically inactive cGVHD but biopsies showing active
GVHD. The CR rate at 9 months was 33% for pred-
nisone and 37% for prednisone/azathioprine. Some
studies have used discontinuation of immunosuppres-
sion as an endpoint, so response data are not available
[8,11].
For our study, the CR and CR 1 PR rates after 9
months of therapy for all patients (both treatment
arms) were 31% and 43%, respectively, for 42 evalu-
able patients. The CR rate is comparable to a study
by Sullivan et al. [7], but the CR 1 PR rate is lower.
Both the CR and CR 1 PR rates are much lower
than those in a study reported by Arora et al. [10]
This may be because of differences in study popula-
tions and the single versus multi-institutional setting.
Of note, 49% of the evaluable patients for whom
data were evaluable in our study had severe disease ac-
cording to the NIH Consensus criteria. Additional
support for the fact that our patient population was
skewed toward more severely affected patients is pro-vided by a comparison to a report of a large cohort
of children with cGVHD [22]. GI and lung involve-
ment were seen in 44% and 20% of our patients and
in 24% and 11% of that cohort, respectively.
Studying cGVHD at the time of initial diagnosis is
a challenge. The initial presentation can be insidious
and often develops at the time of taper of planned
GVHD prophylaxis or aGVHD treatment. The early
symptom complex at presentation can overlap with fea-
tures of aGVHD and other posttransplantation compli-
cations (eg, infection, malabsorption). Subsequent trials
might benefit greatly from the development of bio-
markers specific to cGVHD that confirm the diagnosis
at onset and possibly as surrogate indicators of response.
A pretreatmentwindow that allows a short course of ste-
roids could make more patients eligible for future
‘‘front-line’’ studies and allow a less rushed study entry.
A less rigid and complex steroid taper would provide in-
vestigators with flexibility needed for individual pa-
tients, better reflecting current clinical practice.
The results of studies [2,10,11] inwhich a drugwith
activity in a Phase II salvage study fails to add benefit in
a Phase III up-front treatment study suggest that a
better approach may be needed. One approach is to
perform a randomized Phase II study in the upfront
setting before committing to a large Phase III trial.
The caution is to avoid the assumption that agents
active in the salvage setting will be beneficial at the
time of initial diagnosis. Our study provides response
rates for cGVHD in children in a multicenter trial
setting, which can serve as a baseline for such trials.
The results with the addition of a study drug would
have to be substantially better than the baseline to
warrant a Phase III trial. Finally, our data suggest that
risk stratification based on the NIH consensus staging
is likely to be useful for study design by identifying
patients with severe cGVHD who have little chance
of a complete response with standard therapy and for
whom novel therapies need to be developed and tested.ACKNOWLEDGMENTS
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